GleamWall
中文EN

KMDA KAMADA LTD IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1567529 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.1%
TTM net income YoY39.7%
TTM EPS YoY40.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—

Margins

Gross margin42.3%
Operating margin14.5%
Net margin11.2%
FCF margin—
EBITDA margin15.4%

Returns

ROE7.6%
ROA5.4%
ROIC (approx.)12.1%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets29.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage30.36x

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio-1.4%
Payout ratio114.2%
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-31
Income statement
Revenue$44.68M$47.01M$44.75M$44.02M$39.01M$41.74M$42.47M$37.74M
Cost of revenue$27.71M$27.25M$25.82M$23.27M$21.97M$24.51M$23.52M$20.98M
Gross profit$16.97M$19.76M$18.93M$20.75M$17.03M$17.23M$18.95M$16.75M
R&D expense$2.89M$2.64M$3.22M$4.25M$2.67M$3.41M$4.80M$4.29M
SG&A expense$5.64M$4.82M$4.07M$4.20M$4.12M$4.01M$3.78M$3.79M
Operating income$3.55M$7.82M$7.07M$7.79M$5.08M$5.29M$5.64M$4.04M
Interest expense$259,000$221,000$192,000$192,000$4.76M$167,000$145,000$159,000
Pretax income$4.73M$6.37M$5.75M$6.61M$2.46M$3.95M$4.49M$2.44M
Income tax$1.17M$1.07M-$1.62M$2.65M-$1.35M$84,000$63,000$74,000
Net income$3.56M$5.30M$7.38M$3.96M$3.81M$3.86M$4.43M$2.37M
EBITDA-$5.93M$11.58M$10.82M$11.41M$9.18M$8.54M$8.87M$7.28M
EPS (basic)—0.090.130.07—0.070.080.04
EPS (diluted)—0.090.130.07—0.070.080.04
Balance sheet
Cash & equivalents$75.47M$72.00M$65.98M$76.25M$78.44M$72.00M$56.55M$48.19M
Receivables$27.01M$31.38M$30.50M$27.88M$21.55M$16.30M$26.23M$18.86M
Inventory$84.94M$85.41M$82.08M$78.36M$78.82M$71.56M$78.71M$84.35M
Current assets$193.07M$192.73M$183.27M$188.50M$184.35M$164.41M$166.43M$157.81M
PP&E, netmay include right-of-use assets (IFRS)$41.37M$38.10M$37.89M$37.41M$36.24M$33.75M$31.97M$30.73M
Goodwill$30.31M$30.31M$30.31M$30.31M$30.31M$30.31M$30.31M$30.31M
Intangibles—————$135.04M$136.83M$138,623
Total assets$378.71M$377.21M$368.17M$375.11M$372.25M$351.21M$351.04M$343.17M
Current liabilities$47.39M$47.84M$45.77M$57.05M$49.39M$34.00M$40.90M$37.17M
Short-term debt$9.92M$10.59M$9.85M$10.89M$10.18M$9.48M$12.61M$12.98M
Total liabilities$109.64M$111.98M$108.22M$123.15M$112.79M$95.94M$99.89M$92.02M
Shareholders' equity$269.07M$265.23M$259.95M$251.96M$259.46M$255.27M$251.15M$251.15M
Shares outstanding57.69M———57.51M———
Cash flow statement
Operating cash flow$7.57M$10.42M$8.02M-$513,000$10.40M$22.21M$13.96M$1.02M
Investing cash flow-$2.77M-$3.59M-$2.01M-$1.46M-$2.92M-$2.12M-$3.01M-$2.68M
Financing cash flow-$1.18M-$754,000-$16.12M-$293,000-$708,000-$4.79M-$2.68M-$5.74M
Depreciation & amortization-$9.48M$3.76M$3.75M$3.61M$4.10M$3.24M$3.23M$3.24M
Stock-based compensation$458,000$117,000$95,000$175,000$174,000$224,000$235,000$241,000
Dividends paid$0$0$11.53M$11.53M————

Free plan shows the latest 8 periods; Pro shows all 21 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.